Compugen recalibrates MAIA-ovarian control arm, tightens expectations as data readout nears

Q2 update trims assumed placebo PFS to ~4 months, while AstraZeneca's 12th Phase III for rilvegostomig underscores partnership momentum.

CGEN · Earnings Call · 2026-08-03

Compugen's Q2 2026 update was steady but carried an important statistical recalibration. The company trimmed its assumed placebo median progression-free survival (PFS) for the MAIA-ovarian trial from ~5.5 months to ~4 months, citing emerging external data from two European studies (TEDOVA and OReO). This adjustment signals management is anchoring expectations to a more realistic control arm, potentially raising the bar for COM701's monotherapy effect in platinum-sensitive ovarian cancer.

Control Arm Reset

The change is grounded in two recent trials. As Chief Medical Officer Michelle Mahler explained on the call:

So the 2 trials that we are referring to are European studies. One is TEDOVA recently presented at ASCO and the other trial is a trial called OReO. Both trials are run in Europe and had similar patient populations because they enrolled patients with platinum-sensitive ovarian cancer and were treated in the maintenance setting. However, the patient population was not identical because the trials did not cap the prior lines of treatment.
Michelle Mahler, Chief Medical Officer · 2026-08-03

These trials enrolled more heavily pretreated patients (including those with liver metastases and who had received both bevacizumab and PARP inhibitors), yielding a placebo PFS of 2.8 months. Compugen now estimates its own control arm will deliver ~4 months, a middle ground between the historical 5.5 months from older registration trials and the 2.8 months from these newer, sicker cohorts. The company emphasizes that the trial remains blinded and that the real test is the differential between COM701 and the internal placebo control. As CEO Eran Ophir noted: “As such, we currently don't know who is allocated to which arm because our trial is blinded.” — Eran Ophir, President and Chief Executive Officer · 2026-08-03 This recalibration is a notable shift from the prior call in May, when management cited a benchmark of ~5.5 months and hoped for a 3-month improvement. Now, with a lower control assumption, the same absolute PFS improvement would translate into a larger relative benefit—but also implies that the absolute PFS bar for 'success' may effectively be lower.

The company maintains guidance for the MAIA ovarian interim analysis by Q1 2027, with median PFS as the primary readout. The design also excludes liver metastases, aligning with FDA guidance under Project FrontRunner, which the company believes could support a future accelerated path if data are robust.

Partner Momentum and Pipeline

Beyond the control-arm reset, the quarter highlighted continued momentum with partners. AstraZeneca added a 12th Phase III trial for anti PD 1 /TIGIT bispecific rilvegostomig (derived from Compugen's COM902) in high-risk muscle-invasive urothelial carcinoma, combining with Datroway in the adjuvant setting. This follows encouraging data from the TROPION-PanTumor 03 study. Management noted the ongoing expansion reflects AZ's confidence—the program carries a non-risk-adjusted peak revenue potential of over $5 billion, with $195 million in remaining milestones and tiered royalties for Compugen. During the call, Eran commented on the new trial:

“This doesn't change. I mean, just it's another short-term goal in a new indication in combination with ADC, which is, again, very promising, also based on what you've seen from the Phase II study.” — Eran Ophir, President and Chief Executive Officer · 2026-08-03

Meanwhile, GS-0321 (the anti-IL-18 binding protein antibody licensed to Gilead) continues dose escalation in both monotherapy and combination, with backfill cohorts. The company has received $90 million so far and is eligible for up to $758 million in milestones. Progress underpins the placebo control discipline seen across the pipeline.

Financially, the company ended Q2 with ~$125.3 million in cash and marketable securities, providing runway into 2029 assuming no further inflows. This supports the ongoing MAIA trial, early-stage Unigen-discovered programs, and continued investment in the pipeline.

Outlook

The PARP inhibitor and bevacizumab pretreated population represents a significant unmet need with no approved maintenance option, and Compugen sees this as an opportunity to move earlier in treatment if COM701 demonstrates meaningful single-agent activity. The adjusted control-arm assumption is a pragmatic update that aligns expectations with real-world data, reducing the risk of overpromising on the readout. While the company repeats its Q1 2027 timeline, the recalibration adds a layer of precision to what investors should watch for when the data mature.